Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (251-260 of 627) with videos related to

Pageof 63
Sort By:
Journal of the American College of Cardiology|December 17, 2016
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II RegistryBenjamin A Steinberg, Peter Shrader, Laine Thomas, et al.
Journal of the American College of Cardiology|February 11, 2003
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patientsPadma Kaul, L Kristin Newby, Yuling Fu, et al.
Circulation|December 14, 2021
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADERAhmed M Shaman, Stephen C Bain, George L Bakris, et al.
Circulation. Cardiovascular Quality and Outcomes|September 20, 2012
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trialSteen Husted, Stefan James, Richard C Becker, et al.
American Heart Journal|July 5, 2024
Characterization of peripheral artery disease and associations with traditional risk factors, mobility, and biomarkers in the project baseline health studyJacquelyn B Kercheval, Dennis I Narcisse, Maggie Nguyen, et al.
Circulation. Cardiovascular Interventions|June 18, 2016
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX TrialMuthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Clinical Cardiology|June 13, 2017
Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effortJessie Kittle, Renato D Lopes, Mingyan Huang, et al.
Contemporary Clinical Trials|January 12, 2011
Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trialKenneth W Mahaffey, June L Wampole, Amanda Stebbins, et al.
The American Journal of Cardiology|August 14, 2017
Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)Muthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Journal of Thrombosis and Thrombolysis|May 31, 2015
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trialsDominick J Angiolillo, Deepak L Bhatt, Ph Gabriel Steg, et al.
Pageof 63

Showing results (251-260 of 627) with videos related to

Sort By:
Pageof 63
Journal of the American College of Cardiology|December 17, 2016
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II RegistryBenjamin A Steinberg, Peter Shrader, Laine Thomas, et al.
Journal of the American College of Cardiology|February 11, 2003
Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patientsPadma Kaul, L Kristin Newby, Yuling Fu, et al.
Circulation|December 14, 2021
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADERAhmed M Shaman, Stephen C Bain, George L Bakris, et al.
Circulation. Cardiovascular Quality and Outcomes|September 20, 2012
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trialSteen Husted, Stefan James, Richard C Becker, et al.
American Heart Journal|July 5, 2024
Characterization of peripheral artery disease and associations with traditional risk factors, mobility, and biomarkers in the project baseline health studyJacquelyn B Kercheval, Dennis I Narcisse, Maggie Nguyen, et al.
Circulation. Cardiovascular Interventions|June 18, 2016
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX TrialMuthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Clinical Cardiology|June 13, 2017
Cardiovascular adverse events in the drug-development program of bupropion for smoking cessation: A systematic retrospective adjudication effortJessie Kittle, Renato D Lopes, Mingyan Huang, et al.
Contemporary Clinical Trials|January 12, 2011
Strategic lessons from the clinical event classification process for the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trialKenneth W Mahaffey, June L Wampole, Amanda Stebbins, et al.
The American Journal of Cardiology|August 14, 2017
Cangrelor Versus Clopidogrel on a Background of Unfractionated Heparin (from CHAMPION PHOENIX)Muthiah Vaduganathan, Robert A Harrington, Gregg W Stone, et al.
Journal of Thrombosis and Thrombolysis|May 31, 2015
Impact of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trialsDominick J Angiolillo, Deepak L Bhatt, Ph Gabriel Steg, et al.
Pageof 63